Martti Antila

IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper

Ignacio J. Ansotegui, Giovanni Melioli, Giorgio Walter Canonica et al. · World Allergy Organization Journal · 2020 · 506 citations · Full text

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

William W. Busse, Eugene R. Bleecker, J Mark FitzGerald et al. · The Lancet Respiratory Medicine · 2018 · 298 citations

Asthma, Rheumatology, Extension Trial +10

Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study

Andrew Menzies‐Gow, Michael E. Wechsler, Christopher E. Brightling et al. · The Lancet Respiratory Medicine · 2023 · 127 citations · Full text

Asthma, Rheumatology, Allergy +9

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

Zelalem Temesgen, Charles D. Burger, Jason Baker et al. · The Lancet Respiratory Medicine · 2021 · 70 citations · Full text

Covid-19 Pandemic, Respiratory Infection, Infectious Respiratory Disease +6

Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial

MeiLan K. Han, Martti Antila, Joachim H. Ficker et al. · The Lancet Rheumatology · 2022 · 47 citations · Full text

Clinical Management, Clinical Therapeutic, Symptomatic Treatment +5